An implant for sleep apnea is one of the few CPAP alternatives. This article compares hypoglossal nerve stimulation and ...

The Department of Justice is investigating implant maker Inspire Medical Systems for its marketing, promotion and reimbursement practices, the company disclosed to investors Monday. Inspire, one of ...

Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January ...

During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

Inspire makes mask-free implants to treat obstructive sleep apnea. The implants deliver pulses ... The company plans a full launch of its Inspire V device in 2025 after receiving Food and Drug ...

Inspire Medical Systems is a leader in neurostimulation technology for obstructive sleep apnea; its devices are the only ones of their type with FDA approval. The company is now focused on ...

Inspire expects full-year earnings to be $2.10 to $2.20 per share, with revenue in the range of $940 million to $955 million. This story was generated by Automated Insights ( ...

Inspire (INSP) delivered earnings and revenue surprises of 55.41% and 0.04%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

The global sleep software market valued at US$ 776.2 Million in 2023, is forecasted to grow at a robust CAGR of 10.1%, reaching US$ 878.9 Million in 2024 and an impressive US$ 1,5 ...